undamentalytics Newsletter
Sign in

Lisata Therapeutics, Inc. income statement

In fiscal 2025, Lisata Therapeutics, Inc. reported revenue of $170,000, down 83.0% on the year before, operating income of −$18.2m (a -10711.2% margin) and net income of −$16.6m, or −$1.91 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue7010141518223500100
Cost of revenue5091213162031—————
Gross profit20122224—————
Research and development88101729241713131185
Selling, general and administrative312822223130131413———
General and administrative—————————1210—
Operating income−19−34−30−37−58−114−30−58−26−22−18−16
Interest expense0320122—————
Income before tax−19−35−36−39−56−98−31−57−23−21−18−15
Income tax10−01−0−170−2−2−1−1−0
Net income−23−47−54−39−55−81−33−54−21−20−17−15
Diluted EPS−$0.46−$0.54−$4.00−$1.90−$1.68−$16.67−$4.99−$10.47−$2.58−$2.40−$1.91−$1.64
Diluted shares (average)———————5m8m8m9m9m
EBITDA−14−33−29−36−56−112−29−58−26−22−18−16

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IBIO vs LSTAAIM vs LSTACLDX vs LSTA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lisata Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lisata Therapeutics, Inc.